A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors

News

All the latest news about the Access to Medicine Foundation, our research programmes and engagement activities. 

All Access to Medicine Foundation Access to Medicine Index Antimicrobial Resistance Benchmark Access to Vaccines Index

24 Nov 2015

The Bulletin of WHO publishes an article on the thematic study: hepatitis C by the Access to Medicine Foundation

The Bulletin of the World Health Organization has published the latest study from the Access to Medicine Foundation: on how the world’s largest pharma...

17 Nov 2015

Pharmaceutical companies come to Amsterdam: workshop on latest Index methodology

On 18 and 19 November, the Access to Medicine Foundation will run a workshop in Amsterdam for 20 of the world’s largest pharmaceutical companies with...

29 Oct 2015

2016 Access to Medicine Index to place high emphasis on how pharmaceutical companies perform

Globally, 2 billion people still cannot access the medicine they need. The world’s leading pharmaceutical companies have an important role to play in...

16 Jun 2015

2015 Methodology Review: independent experts meet to evaluate next Index methodology

On 17 June, the Expert Review Committee will gather in Haarlem to review key methodology proposals for the next Access to Medicine Index and the first...

13 May 2015

2015 Methodology Review: targeting key aspects of the Index analysis

The 2015 Methodology Review began in January with a series of checks on the analytical approach used for the 2014 Access to Medicine Index. During the...

09 Apr 2015

New Research: How pharmaceutical companies address access to maternal and reproductive health

Every day, an estimated 800 women die during pregnancy and childbirth due to preventable causes – most of whom live in developing countries. Today, th...

31 Mar 2015

April 9: WHO seminar on Access to Medicine Index; BioPharma Sustainability Roundtable

In April, representatives of the Access to Medicine Foundation have been invited to lead a WHO seminar in Geneva and speak at the BioPharma Sustainabi...

10 Feb 2015

Pharma companies discuss 2014 Index performances

The 2014 Access to Medicine Index identifies clear opportunities for pharmaceutical companies to improve access to their products. During a month of i...

26 Jan 2015

Recap: launch of the 2014 Access to Medicine Index

In the three months since its publication, the 2014 Access to Medicine Index report has been welcomed as a balanced and detailed report on pharmaceuti...

22 Jan 2015

2014 Access to Medicine Index at the European Parliament – open invitation

On 4 February, the 2014 Access to Medicine Index will be launched at the European Parliament in Brussels by Wim Leereveld, Index CEO and founder, and...

19 Jan 2015

Davos 2015: Wim Leereveld on health systems design

On January 22, during the World Economic Forum Annual Meeting, Index CEO and founder Wim Leereveld will be in Davos to discuss health systems leap-fro...

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |